Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 4, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Varian Medical Systems Inc. (NYSE: VAR), Mylan Inc. (NASDAQ: MYL), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Abiomed Inc. (NASDAQ: ABMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On November 26, 2013, Merck & Co. Inc. (Merck) announced that its Board of Directors has increased the Company's quarterly dividend to $0.44 per outstanding share of the Company's common stock, up $0.01 from $0.43 per outstanding share paid previously. The Company stated that the payment will be made on January 8, 2014, to stockholders of record at the close of business on December 16, 2013. According to Merck, the last dividend increase was announced in November 2012, when the Board raised the dividend from $0.42 to $0.43 per common share. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

Varian Medical Systems Inc. Research Report

On November 25, 2013, Varian Medical Systems Inc. (Varian) announced that the Company has installed the latest version of its advanced TrueBeam radiotherapy and radiosurgery system at The Clatterbridge Cancer Centre near Liverpool. The Company informed that the TrueBeam system 2.0 is an infrastructure that enables integration and control of Varian's PerfectPitch six degrees of freedom couch, use of advanced IGRT and motion management capabilities, connectivity for real-time tracking solutions, and a new low-energy and low-dose imaging beam, all of which combine to offer fast and precise treatments. Varian also mentioned that the cancer center recently reached a milestone when a 71-year-old woman from North Wales became the 100th lung cancer patient to be treated using advanced stereotactic ablative body radiotherapy (SABR) techniques - an advanced procedure used primarily to target small, early stage lung tumors, enabled by Varian's state-of-the-art equipment. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bd48_VAR

Mylan Inc. Research Report

On December 1, 2013, Mylan Inc. (Mylan) along with the Elton John AIDS Foundation (EJAF) announced that they will give a combined $1 million to the Business Leadership Council for a Generation Born HIV Free (BLC), for the elimination of mother-to-child transmission (eMTCT) of HIV in Nigeria. The Company stated that Nigeria is home to 3.4 million people living with HIV, with approximately 60,000 children newly infected with the virus in 2012 alone, the highest in any nation in the world. The Company further stated that for many years, the mother-to-child transmission rate there has remained at 30%, while other countries (ranging from the U.S. to Botswana) have virtually eliminated mother-to-child transmission of HIV. Mylan CEO Heather Bresch commented, "Mylan is proud to commemorate World AIDS Day by announcing this important partnership with EJAF and BLC to reach more HIV-positive pregnant women in Nigeria. Ending transmission of HIV from mother to child is an important step in ending AIDS. Mylan's mission is to provide the world's 7 billion people access to high quality medicine, and we have long been dedicated to ensuring access to affordable, life-saving antiretroviral medicines (ARVs)." The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5a20_MYL

Achillion Pharmaceuticals, Inc. Research Report

Achillion Pharmaceuticals, Inc. (Achillion) posted in the events section of its website that it will be participating at the Piper Jaffray Healthcare Conference on December 4, 2013. Achillion's President and CEO Milind Deshpande, Ph.D. will represent the Company and is scheduled to present at 12:30 p.m. The Full Research Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/04a2_ACHN

Abiomed Inc. Research Report

On November 26, 2013, Abiomed Inc. (Abiomed) announced that its Chairman, President and CEO Michael R. Minogue will present at the 25th Annual Piper Jaffray Healthcare Conference on December 4, 2013 at 8:00 a.m. EST. The Company said that the conference will be held at The New York Palace Hotel in New York. The Full Research Report on Abiomed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea34_ABMD

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.